Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes
Diabetes Care2009Vol. 32(12), pp. 2251–2257
Citations Over TimeTop 10% of 2009 papers
Kristina I. Rother, Lisa M. Spain, Robert Wesley, Benigno J. Digon, Alain Baron, Kim Chen, Patric Nelson, H. M. Dosch, Jerry P. Palmer, Barbara Brooks‐Worrell, Michael Ring, David M. Harlan
Abstract
In long-standing type 1 diabetes, which remains an active autoimmune disease even decades after its onset, surviving beta-cells secrete insulin in a physiologically regulated manner. However, the combination of intensified insulin therapy, exenatide, and daclizumab did not induce improved function of these remaining beta-cells.
Related Papers
- → Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes(2012)39 cited
- → Incretin-based therapies in type 2 diabetes: A review of clinical results(2008)23 cited
- → Glucagon‐like peptide‐1‐based therapies: new developments and emerging data(2008)13 cited
- → Exploring the Value and Costs of Incretin-Based Therapies(2014)
- [Therapy with incretin mimetic exenatide. Soon HbA1c value and weight decrease permanently].(2006)